| 000 | 02735nam a22004455i 4500 | ||
|---|---|---|---|
| 001 | 978-3-642-14136-2 | ||
| 003 | DE-He213 | ||
| 005 | 20140220083745.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 110411s2011 gw | s |||| 0|eng d | ||
| 020 |
_a9783642141362 _9978-3-642-14136-2 |
||
| 024 | 7 |
_a10.1007/978-3-642-14136-2 _2doi |
|
| 050 | 4 | _aRC261-271 | |
| 072 | 7 |
_aMJCL _2bicssc |
|
| 072 | 7 |
_aMED062000 _2bisacsh |
|
| 082 | 0 | 4 |
_a614.5999 _223 |
| 100 | 1 |
_aDranoff, Glenn. _eeditor. |
|
| 245 | 1 | 0 |
_aCancer Immunology and Immunotherapy _h[electronic resource] / _cedited by Glenn Dranoff. |
| 264 | 1 |
_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2011. |
|
| 300 |
_aXIV, 306 p. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 |
_aCurrent Topics in Microbiology and Immunology, _x0070-217X ; _v344 |
|
| 520 | _aThe recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These “first-in-class” treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy. | ||
| 650 | 0 | _aMedicine. | |
| 650 | 0 | _aOncology. | |
| 650 | 0 | _aImmunology. | |
| 650 | 1 | 4 | _aBiomedicine. |
| 650 | 2 | 4 | _aCancer Research. |
| 650 | 2 | 4 | _aImmunology. |
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9783642141355 |
| 830 | 0 |
_aCurrent Topics in Microbiology and Immunology, _x0070-217X ; _v344 |
|
| 856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-3-642-14136-2 |
| 912 | _aZDB-2-SBL | ||
| 999 |
_c106934 _d106934 |
||